Optimization of Hypercholesterolemia Treatment after Heart Transplant: The Role of PCSK9 Inhibitors.

María Jesús Valero MasaCarlos David Ortiz-BautistaJavier CastrodezaManuel Martinez-Selles

Published in: Current pharmaceutical design (2024)

PCSK9 inhibitors are safe and effective in reducing LDL in HT patients. However, larger studies are needed to clarify if they can reduce the development of coronary allograft vasculopathy.

Keyphrases

end stage renal disease
low density lipoprotein
ejection fraction
newly diagnosed
chronic kidney disease
coronary artery disease
coronary artery
heart failure
atrial fibrillation
aortic stenosis
left ventricular
case control